Evaluation of the clinical relevance of the quantitative assay of serum intact immunoglobulins using the Hevylite chain assay in the diagnosis and disease monitoring of plasma cell dyscrasia

Evaluation of the clinical relevance of the quantitative assay of serum intact immunoglobulins using the Hevylite chain assay in the diagnosis and disease monitoring of plasma cell dyscrasia - Hevylite study in PCD

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000023220

Enrollment

Registered

2016-07-20

Start date

2016-07-11

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

plasma cell dyscrasia

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Multiple Myeloma Waldenstrom's Macroglobulinemia

Exclusion criteria

Exclusion criteria: We have not set up the exclusion criteria.

Design outcomes

Primary

Measure	Time frame
The value and the ratio of HLC (Hevylite chain).	—

Countries

Japan

Contacts

Public ContactYoshikazu Kamiya

National Hospital Organization, Higashi Nagoya National Hospital Division of Hematology and Oncology

yskzkmy@e-nagoya.hosp.go.jp+81-52-801-1151

Outcome results